Clinical Trial

Study of Perioperative Dostarlimab in Participants With Untreated T4N0 or Stage III dMMR/MSI-H Resectable Colon Cancer

Name: Study of Perioperative Dostarlimab in Participants With Untreated T4N0 or Stage III dMMR/MSI-H Resectable Colon Cancer — clinical trial record (NCT05855200)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Recruiting Phase 3

View on ClinicalTrials.gov →

Summary

The primary purpose of this study is to evaluate the efficacy of perioperative dostarlimab compared with standard of care (SOC) in participants with untreated T4N0 or Stage III (resectable), defective mismatch repair/ microsatellite instability high (dMMR/MSI-H) colon cancer.

Trial Details

NCT Number	NCT05855200
Lead Sponsor	GlaxoSmithKline
Conditions	Colonic Neoplasms, Neoplasms, Colon
Enrollment	892 participants
Start Date	2023-08-01
Primary Completion	2029-03-19 (estimated)
Study Completion	2031-03-27 (estimated)
Updated on ClinicalTrials.gov	2026-01-23